Three (5.6%) of 53 patients who received dualtreatments had moderate QTc prolongation and two patients had critical qtc prolongation.Torsades de pointes was not detected among the patients.Conclusion: Close ECG monitoring is necessary, and the frequency of ECG monitorizationshould be individualized in patients receiving azithromycin with hydroxychloroquine.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Background: Hydroxychloroquine (HQN) and azithromycin (AZ) were used in the treatmentof coronavirus disease 2019 (Covid-19), which might lead to cardiac side effects.Aim: We aimed to describe the safety of HQN and HQN+AZ in terms of cardiac events.Materials and methods: The QTc intervals were calculated by examining the ecg records ofthe first day and fifth day of hospitalization the patients who received HQN with or withoutconcominant AZ for treatment of Covid 19.Results: We included 93 patients.Moderate QTc prolongation was detected in 3 (7.5%) of40 patients who received hydroxychloroquine monotherapy for five days.
📊
Temel Bulgular & Veri:Critical qtcprolongation was not detected in any patient.
💡
Sonuç & Katkı:Three (5.6%) of 53 patients who received dualtreatments had moderate QTc prolongation and two patients had critical qtc prolongation.Torsades de pointes was not detected among the patients.Conclusion: Close ECG monitoring is necessary, and the frequency of ECG monitorizationshould be individualized in patients receiving azithromycin with hydroxychloroquine.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri
Abstract
Background: Hydroxychloroquine (HQN) and azithromycin (AZ) were used in the treatmentof coronavirus disease 2019 (Covid-19), which might lead to cardiac side effects.Aim: We aimed to describe the safety of HQN and HQN+AZ in terms of cardiac events.Materials and methods: The QTc intervals were calculated by examining the ecg records ofthe first day and fifth day of hospitalization the patients who received HQN with or withoutconcominant AZ for treatment of Covid 19.Results: We included 93 patients.Moderate QTc prolongation was detected in 3 (7.5%) of40 patients who received hydroxychloroquine monotherapy for five days. Critical qtcprolongation was not detected in any patient. Three (5.6%) of 53 patients who received dualtreatments had moderate QTc prolongation and two patients had critical qtc prolongation.Torsades de pointes was not detected among the patients.Conclusion: Close ECG monitoring is necessary, and the frequency of ECG monitorizationshould be individualized in patients receiving azithromycin with hydroxychloroquine.
🔖
Bu Makaleye Atıf Yap
DURAL, İ. E., NADİR, Y. (2022). Adverse Cardiac Events Among thePatients Using Hydroxychloroquine andAzithromycin in COVID-19. Infectious diseases and clinical microbiology (Online), Cilt: 2 - Sayı: 3, 158–162. https://ajindex.com/articles/539107
1 Demirbilek Y, Pehlivantürk G, Özgüler ZÖ, Alp Meşe E. COVID-19 outbreak control, example of ministry of health of Turkey. Turk J Med Sci 2020; 50: 489-94. 2 Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020; 21: 343-60. 3 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 2020; 34: 101663. 4 Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 2017; 16: 411-19. 5 Bakheit AH, Al-Hadiya BM, Abd-Elgalil AA. Azithromycin. Profiles Drug Subst Excip Relat Methodol 2014; 39: 1-40. 6 Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol 2006; 44: 173-5 7 Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk evaluation of azithromycin-induced QT prolongation in real-world practice. Biomed Res Int 2018; 2018: 1574806. 8 Zengin R, Sarıkaya ZT, Karadağ N, Çuhadaroğlu Ç, Ergönül Ö, Kocagöz S. Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and Treatment of COVID-19. Infect Dis Clin Microbiol 2020; 1: 24-26. 9 Çelik HG, Keske Ş, Şener Ü, Tekbaş M, Kapmaz M, Şahin ŞT, et al. Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic? Int J Infect Dis. 2020 Oct 29;102:389-391. doi: 10.1016/j.ijid.2020.10.080. 10 Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42: 145-53. 11 Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 2018; 41: 919-31. 12 Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020: 5: 1036-41. 13 Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, et al. Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythm Electrophysiol 2017; 10: e003560.